The University of Cincinnati's Genome Research Institute and Girindus USA, a maker of pharmaceutical ingredients, are also located on the campus.
Under the agreement, expected to close in December, Patheon will continue to manufacture and supply the Aventis products currently made at that location. According to published reports, it plans to invest $23 million in renovations and improvements.
The state is providing Patheon with a $9-million Ohio Enterprise bond fund for a 15-year term; a $3-million, 10-year loan at 3% interest; a 70% tax credit over 10 years, which is valued at approximately $2.5 million, and an undisclosed sum for job training.
Patheon is a global provider of outsourced drug development and manufacturing services to pharmaceutical and biotechnology companies. Aventis is a developer of pharmaceutical products with US headquarters in Bridgewater, NJ.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
